Satya Pharma and Alivexis have discovered a highly selective, safe and best-in-class PKMYT1 inhibitor for CCNE-1 amplified and other bio-marker identified tumors
Satyarx Pharma Innovations Private Limited (“Satya Pharma”), an oncology biotech, and Alivexis, Inc. (formerly known as Modulus Discovery, Inc.), a global biotech company based in Japan and Boston, USA, entered into a preclinical collaboration in May 2023 to develop a best-in-class PKMYT1 inhibitor.
Under the terms of the agreement, the companies co-funded and developed a pre-clinical candidate selectively targeting PKMYT-1, while sparing Wee1 and other related proteins.
PKMYT1 inhibitors are a novel class of therapeutics designed to target CCNE1-amplified cancers, a significant unmet medical need.
This uniquely structured collaboration drew on the collective expertise of Satya and Alivexis, including Alivexis’ Intelligent Supercomputing capabilities and the experienced drug discovery team at Satya
The candidate and backup compounds are distinct from other reported compounds in terms of selectivity over Wee1 and related kinases, resulting in excellent efficacy, significantly improved safety and druggability. Furthermore, the wide therapeutic window exhibited in preclinical studies highlights the potential of the molecule to be used either as a single agent or in combination with existing standard or care drugs across selected cancers
The program, now part of Alivexis portfolio (ALVX-A), is available for partnering
About Satya Pharma
Satya was started in Aug 2020 as an oncology biotech. It is focused on DDR pathways and on developing therapeutics that are First-in-class or with a novel mode of binding. Satya’s objective is to discover drugs with the potential to address cancers by directly targeting important biological pathways implicated in oncogenesis or resistance mechanisms, thereby presenting novel and high-impact opportunities for treatment across indications.
About Alivexis
Alivexis, Inc. is a technology-driven drug discovery enterprise with operational foundations in both Japan and the US. By merging state-of-the-art drug discovery platforms including ModBindTM, which is a highly accelerated accurate and absolute simulation method, with profound knowledge of disease biology and a dynamic global business approach, Alivexis is propelling forward a distinct portfolio of small molecule drugs along with a variety of research and development collaborations. At present, Alivexis is dedicated to swiftly bringing innovative medications to individuals and their families grappling with cancer, both chronic and acute immune-inflammatory conditions, and rare diseases. Recently out-licensed its Cathepsin C clinical candidate developed for neutrophil-driven inflammatory disorders to Melodia Therapeutics for a value of upto 245 million USD.
Managed by a team with broad experience across pharmaceutical and biotech sectors in Japan and the U.S., Alivexis embodies a collaborative, network-based approach to drug discovery.
